{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:46:20Z","timestamp":1766407580123,"version":"3.40.2"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"DOI":"10.7759\/cureus.81113","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T01:42:03Z","timestamp":1742866923000},"source":"Crossref","is-referenced-by-count":1,"title":["Cryptococcus neoformans in Chronic Lymphocytic Leukemia (CLL) Treated With Ibrutinib: A Combo Gone Wrong!"],"prefix":"10.7759","author":[{"given":"Yogesh","family":"Yadav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Centellas Montano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Plocharczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"MacQueen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SushilKumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950101)75:1+<381::aid-cncr2820751320>3.0.co;2-b","article-title":"Leukemias, myeloma, and other lymphoreticular neoplasms","volume":"75","author":"Hern\u00e1ndez JA","year":"1995","unstructured":"Hern\u00e1ndez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995, 75:381-94. 10.1002\/1097-0142(19950101)75:1+&lt;381::aid-cncr2820751320&gt;3.0.co;2-b","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2695","article-title":"Ibrutinib in the treatment of chronic lymphocytic leukemia: 5\u2009years on","volume":"38","author":"Molica S","year":"2020","unstructured":"Molica S, Matutes E, Tam C, Polliack A. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5\u2009years on. Hematol Oncol. 2020, 38:129-36. 10.1002\/hon.2695","journal-title":"Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0952-7915(97)80107-0","article-title":"Role of Btk in B cell development and signaling","volume":"9","author":"Desiderio S","year":"1997","unstructured":"Desiderio S. Role of Btk in B cell development and signaling. Curr Opin Immunol. 1997, 9:534-40. 10.1016\/s0952-7915(97)80107-0","journal-title":"Curr Opin Immunol"},{"key":"ref4","unstructured":"IMBRUVICA\u00ae (ibrutinib) capsules, for oral use. (2017). Accessed. March 24, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205552s016lbl.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.07.005","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis","volume":"50","author":"Brochard J","year":"2020","unstructured":"Brochard J, Morio F, Mahe J, et al.. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis. Med Mal Infect. 2020, 50:742-5. 10.1016\/j.medmal.2020.07.005","journal-title":"Med Mal Infect"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-620864","article-title":"Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis","volume":"127","author":"Parikh SA","year":"2016","unstructured":"Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016, 127:1752-60. 10.1182\/blood-2015-10-620864","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13933","article-title":"The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL research consortium experience","volume":"173","author":"Van Dyke DL","year":"2016","unstructured":"Van Dyke DL, Werner L, Rassenti LZ, et al.. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL research consortium experience. Br J Haematol. 2016, 173:105-13. 10.1111\/bjh.13933","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201514","article-title":"Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection","volume":"189","author":"Rohatgi S","year":"2012","unstructured":"Rohatgi S, Pirofski LA. Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J Immunol. 2012, 189:5820-30. 10.4049\/jimmunol.1201514","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00265-13","article-title":"X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection","volume":"4","author":"Szymczak WA","year":"2013","unstructured":"Szymczak WA, Davis MJ, Lundy SK, Dufaud C, Olszewski M, Pirofski LA. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. mBio. 2013, 4:e00265-13. 10.1128\/mBio.00265-13","journal-title":"mBio"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.1.144-151.2006","article-title":"Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages","volume":"74","author":"Chang ZL","year":"2006","unstructured":"Chang ZL, Netski D, Thorkildson P, Kozel TR. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages. Infect Immun. 2006, 74:144-51. 10.1128\/IAI.74.1.144-151.2006","journal-title":"Infect Immun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese T","year":"2018","unstructured":"Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, Redelman-Sidi G. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018, 67:687-92. 10.1093\/cid\/ciy175","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/287789-cryptococcus-neoformans-in-chronic-lymphocytic-leukemia-cll-treated-with-ibrutinib-a-combo-gone-wrong","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T01:42:06Z","timestamp":1742866926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/287789-cryptococcus-neoformans-in-chronic-lymphocytic-leukemia-cll-treated-with-ibrutinib-a-combo-gone-wrong"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.81113","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}